Fundz

Who to call at Candel Therapeutics, and when

Fundz watches for the moments Candel Therapeutics starts buying, and tells you who to reach.

  • An alert the day Candel Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Candel Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 20, 2025

Contract Type

partnership

NeedhamBiotechnologyHealth CareTherapeuticsBiopharma

Description

Candel Therapeutics, Inc. and IDEA Pharma have announced a strategic commercial partnership to advance the path-to-market commercialization efforts for CAN-2409, following positive phase 3 data for CAN-2409 in intermediate-to-high risk, localized prostate cancer.

Company Information

Company

Candel Therapeutics

Location

Needham, Massachusetts, United States

About

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company is known for its first-in-class oncolytic viral immunotherapy candidate, CAN-3110, which targets Nestin-positive tumors. They aim to extend cancer treatment options beyond traditional methods and focus on innovative therapeutic approaches. Candel aims to address unmet medical needs in oncology with its experimental medicines.

Related People

Charles
Likely contact at this company
••••••••@••••••••

See Charles's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Candel Therapeutics's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Candel Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.